Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy

SIMPLE SUMMARY: A phase 3 IMbrave150 trial showed that atezolizumab plus bevacizumab combination therapy had an improved survival benefit over sorafenib. An excellent direct anti-cancer effect, including progression-free survival and objective response rate, was also observed with this combination t...

Descripción completa

Detalles Bibliográficos
Autor principal: Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582435/
https://www.ncbi.nlm.nih.gov/pubmed/34771637
http://dx.doi.org/10.3390/cancers13215475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582435/
https://www.ncbi.nlm.nih.gov/pubmed/34771637
http://dx.doi.org/10.3390/cancers13215475

Ejemplares similares